SCHEMBL17470686

SCHEMBL17470686

NCCOc1ccc(/C(=C(\Cl)c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 12/20 0.69
▸ ESR1 P03372 11/20 0.69
▸ ESR2 Q92731 9/20 0.69
▸ CYP3A4 P08684 2/20 0.64
▸ KCNH2 Q12809 2/20 0.63
▸ EBP Q15125 2/20 0.63
▸ SIGMAR1 Q99720 2/20 0.63
▸ CHRM2 P08172 2/20 0.63
▸ ADRA2A P08913 2/20 0.63
▸ ADORA3 P0DMS8 2/20 0.63
▸ CHRM1 P11229 2/20 0.63
▸ PTGS1 P23219 2/20 0.63
▸ SLC6A2 P23975 2/20 0.63
▸ SLC6A4 P31645 2/20 0.63
▸ DRD3 P35462 2/20 0.63
▸ HTR6 P50406 2/20 0.63
▸ SLC6A3 Q01959 2/20 0.63
▸ KMT2A Q03164 2/20 0.63
▸ IDH1 O75874 1/20 0.63
▸ EGFR P00533 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17152214 0.94 CYP19A1 (0.81) CYP19A1ESR1ESR2CYP3A4KCNH2
SCHEMBL8639618 0.84 ESR1 (0.63) CYP19A1ESR1ESR2CYP3A4KCNH2
SCHEMBL8613926 0.84 ESR1 (0.63) CYP19A1ESR1ESR2CYP3A4KCNH2
SCHEMBL8639615 0.84 ESR1 (0.63) CYP19A1ESR1ESR2CYP3A4KCNH2
SCHEMBL17790416 0.84 ESR1 (0.72) CYP19A1ESR1ESR2CYP3A4KCNH2
SCHEMBL17790415 0.84 ESR1 (0.72) CYP19A1ESR1ESR2CYP3A4KCNH2
SCHEMBL8639612 0.84 ESR1 (0.63) CYP19A1ESR1ESR2CYP3A4KCNH2
SCHEMBL8644016 0.83 ESR1 (0.62) CYP19A1ESR1ESR2KCNH2EBP
SCHEMBL8644014 0.83 ESR1 (0.62) CYP19A1ESR1ESR2KCNH2EBP
SCHEMBL8644018 0.83 ESR1 (0.62) CYP19A1ESR1ESR2KCNH2EBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016014812-A1 TREATING ANDROGEN DEPRIVATION THERAPY INDUCED HOT FLASHES AND BONE LOSS USING CIS-CLOMIPHENE ASPEN PARK PHARMACEUTICALS, INC. (US) 2016-01-28 — — WO disclosed
Send feedback